Final results of a randomized multicenter phase II study of alvocidib, cytarabine, and mitoxantrone versus cytarabine and daunorubicin (7 + 3) in newly diagnosed high-risk acute myeloid leukemia (AML)

Joshua F. Zeidner, Matthew C. Foster, Amanda L. Blackford, Mark R. Litzow, Lawrence E. Morris, Stephen A. Strickland, Jeffrey E. Lancet, Prithviraj Bose, M. Yair Levy, Raoul Tibes, Ivana Gojo, Christopher Gocke, Gary Rosner, Richard F. Little, John J. Wright, L. Austin Doyle, B Douglas Smith, Judith Karp

Research output: Contribution to journalLetter

Original languageEnglish (US)
Pages (from-to)92-95
Number of pages4
JournalLeukemia Research
Volume72
DOIs
StatePublished - Sep 1 2018

Fingerprint

alvocidib
Mitoxantrone
Daunorubicin
Cytarabine
Acute Myeloid Leukemia

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Cite this

Final results of a randomized multicenter phase II study of alvocidib, cytarabine, and mitoxantrone versus cytarabine and daunorubicin (7 + 3) in newly diagnosed high-risk acute myeloid leukemia (AML). / Zeidner, Joshua F.; Foster, Matthew C.; Blackford, Amanda L.; Litzow, Mark R.; Morris, Lawrence E.; Strickland, Stephen A.; Lancet, Jeffrey E.; Bose, Prithviraj; Levy, M. Yair; Tibes, Raoul; Gojo, Ivana; Gocke, Christopher; Rosner, Gary; Little, Richard F.; Wright, John J.; Doyle, L. Austin; Smith, B Douglas; Karp, Judith.

In: Leukemia Research, Vol. 72, 01.09.2018, p. 92-95.

Research output: Contribution to journalLetter

Zeidner, Joshua F. ; Foster, Matthew C. ; Blackford, Amanda L. ; Litzow, Mark R. ; Morris, Lawrence E. ; Strickland, Stephen A. ; Lancet, Jeffrey E. ; Bose, Prithviraj ; Levy, M. Yair ; Tibes, Raoul ; Gojo, Ivana ; Gocke, Christopher ; Rosner, Gary ; Little, Richard F. ; Wright, John J. ; Doyle, L. Austin ; Smith, B Douglas ; Karp, Judith. / Final results of a randomized multicenter phase II study of alvocidib, cytarabine, and mitoxantrone versus cytarabine and daunorubicin (7 + 3) in newly diagnosed high-risk acute myeloid leukemia (AML). In: Leukemia Research. 2018 ; Vol. 72. pp. 92-95.
@article{3a039fa94c7149c79108c8126719f983,
title = "Final results of a randomized multicenter phase II study of alvocidib, cytarabine, and mitoxantrone versus cytarabine and daunorubicin (7 + 3) in newly diagnosed high-risk acute myeloid leukemia (AML)",
author = "Zeidner, {Joshua F.} and Foster, {Matthew C.} and Blackford, {Amanda L.} and Litzow, {Mark R.} and Morris, {Lawrence E.} and Strickland, {Stephen A.} and Lancet, {Jeffrey E.} and Prithviraj Bose and Levy, {M. Yair} and Raoul Tibes and Ivana Gojo and Christopher Gocke and Gary Rosner and Little, {Richard F.} and Wright, {John J.} and Doyle, {L. Austin} and Smith, {B Douglas} and Judith Karp",
year = "2018",
month = "9",
day = "1",
doi = "10.1016/j.leukres.2018.08.005",
language = "English (US)",
volume = "72",
pages = "92--95",
journal = "Leukemia Research",
issn = "0145-2126",
publisher = "Elsevier Limited",

}

TY - JOUR

T1 - Final results of a randomized multicenter phase II study of alvocidib, cytarabine, and mitoxantrone versus cytarabine and daunorubicin (7 + 3) in newly diagnosed high-risk acute myeloid leukemia (AML)

AU - Zeidner, Joshua F.

AU - Foster, Matthew C.

AU - Blackford, Amanda L.

AU - Litzow, Mark R.

AU - Morris, Lawrence E.

AU - Strickland, Stephen A.

AU - Lancet, Jeffrey E.

AU - Bose, Prithviraj

AU - Levy, M. Yair

AU - Tibes, Raoul

AU - Gojo, Ivana

AU - Gocke, Christopher

AU - Rosner, Gary

AU - Little, Richard F.

AU - Wright, John J.

AU - Doyle, L. Austin

AU - Smith, B Douglas

AU - Karp, Judith

PY - 2018/9/1

Y1 - 2018/9/1

UR - http://www.scopus.com/inward/record.url?scp=85051399141&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85051399141&partnerID=8YFLogxK

U2 - 10.1016/j.leukres.2018.08.005

DO - 10.1016/j.leukres.2018.08.005

M3 - Letter

C2 - 30118897

AN - SCOPUS:85051399141

VL - 72

SP - 92

EP - 95

JO - Leukemia Research

JF - Leukemia Research

SN - 0145-2126

ER -